Document Detail

Drug treatment of the negative symptoms of schizophrenia.
MedLine Citation:
PMID:  9452938     Owner:  NLM     Status:  MEDLINE    
The traditional antipsychotics are generally poorly effective or ineffective against the negative symptoms of schizophrenia and are also associated with extensive side effects which can themselves cause or exacerbate secondary negative symptomatology. As well as having a low propensity to cause extrapyramidal side effects (EPS), the currently available, putative, atypical antipsychotics (clozapine, risperidone, sertindole, and olanzapine), developmental antipsychotics (zotepine, quetiapine and ziprasidone) and low doses of certain traditional antipsychotics, such as amisulpride and fluphenazine, have been reported to ameliorate negative symptoms in comparison with placebo or standard antipsychotics such as fluphenazine, haloperidol or perphenazine. To date, few trials have specifically examined primary negative symptomatology and it has been suggested that the improvements observed with these drugs may be related to decreases in positive symptoms and/or reduced sedation or extrapyramidal side effects. Although atypicality has been ascribed to 5-HT2/D2 antagonism, the exact pharmacological mechanism(s) underlying the efficacy of the atypical antipsychotics have not been elucidated. Many of these drugs bind to multiple other receptors and/or inhibit neurotransmitter uptake and it seems probable that some of these other pharmacological properties may also contribute to their clinical features.
D J King
Related Documents :
19189878 - Reduction of functional disability with atypical antipsychotic treatment: a randomized ...
15949658 - The crossover approach to switching antipsychotics: what is the evidence?
22536888 - Vitamin d, parathyroid hormone, serum calcium and phosphorus in patients with schizophr...
9442338 - Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-n-n-pr...
23756608 - Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant ne...
25471468 - Efficacy of benzydamine oral rinse in prevention and management of radiation-induced or...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology     Volume:  8     ISSN:  0924-977X     ISO Abbreviation:  Eur Neuropsychopharmacol     Publication Date:  1998 Feb 
Date Detail:
Created Date:  1998-03-05     Completed Date:  1998-03-05     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  9111390     Medline TA:  Eur Neuropsychopharmacol     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  33-42     Citation Subset:  IM    
Department of Therapeutics and Pharmacology, Queen's University of Belfast, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antipsychotic Agents / therapeutic use*
Schizophrenia / drug therapy*
Schizophrenic Psychology*
Reg. No./Substance:
0/Antipsychotic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Locomotor and antidepressant-like effects of 5-HT(1A) agonist LY 228729 in prenatally benzodiazepine...
Next Document:  Increased motor response to cocaine administration following recovery from chronic corticosterone tr...